SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).

被引：0
|
作者：
Garland, Linda L.
Ou, Sai-Hong
Moon, James
Mack, Philip C.
Testa, Joseph
Tsao, Anne S.
Wozniak, Antoinette J.
Gandara, David R.
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[2] UC Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Orange, CA USA
[3] Southwest Oncol Grp Stat Ctr, Seattle, WA USA
[4] Univ Calif Davis, Sacramento, CA 95817 USA
[5] Fox Chase Canc Ctr, Buckingham, PA USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[8] UC Davis Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7083
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
    Ou, Sai-Hong Ignatius
    Moon, James
    Garland, Linda L.
    Mack, Philip C.
    Testa, Joseph R.
    Tsao, Anne S.
    Wozniak, Antoniette J.
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 387 - 391
  • [2] Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
    Johnston, P. B.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Micallef, I. N.
    Porrata, L. F.
    LaPlant, B. R.
    Geyer, S. M.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)
    Druce, M. R.
    Kaltsas, G. A.
    Fraenkel, M.
    Gross, D. J.
    Grossman, A. B.
    HORMONE AND METABOLIC RESEARCH, 2009, 41 (09) : 697 - 702
  • [4] EFFECTS OF MTOR INHIBITOR EVEROLIMUS (RAD001) ON BLADDER CANCER CELLS
    Chiong, Edmund
    Lee, I-Ling
    Dadbin, Ali
    Sabichi, Anita L.
    McConkey, David J.
    Grossman, H. Barton
    JOURNAL OF UROLOGY, 2009, 181 (04) : 406 - 406
  • [5] Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
    Chiong, Edmund
    Lee, I-Ling
    Dadbin, Ali
    Sabichi, Anita L.
    Harris, Loleta
    Urbauer, Diana
    McConkey, David J.
    Dickstein, Rian J.
    Cheng, Tiewei
    Grossman, H. Barton
    CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2863 - 2873
  • [6] A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia
    Ghobrial, Irene M.
    Gertz, Morie A.
    LaPlant, Betsy
    Camoriano, John
    Hayman, Suzanne R.
    Lacy, Martha Q.
    Chuma, Stacey
    Sheehy, Patricia
    Harris, Brianna
    Leduc, Renee
    Rourke, Meghan
    Ansell, Stephen M.
    DeAngelo, Daniel J.
    Dispenzieri, Angela
    Bergsagel, Leif
    Reeder, Craig B.
    Anderson, Kenneth C.
    Richardson, Paul
    Treon, Steven
    Witzig, Thomas E.
    BLOOD, 2009, 114 (22) : 244 - 244
  • [7] Phase II trial of the oral mTOR inhibitor RAD001 (everolimus) in relapsed and/or refractory Waldenstrom Macroglobulinemia: Preliminary results
    Ghobrial, Irene M.
    Leduc, Renee
    Nelson, Marybeth
    Leleu, Xavier
    Jacobsen, Eric
    LaCasce, Ann
    DeAngelo, Daniel
    Fisher, David
    Brown, Jennifer R.
    Schlossman, Robert
    Warren, Diane
    Soumerai, Jacob
    O'Connor, Kelly
    Munshi, Nikhil
    Richardson, Paul
    Anderson, Kenneth C.
    Witzig, Thomas E.
    Treon, Steven P.
    BLOOD, 2007, 110 (11) : 195B - 196B
  • [8] Role of the Novel mTOR Inhibitor RAD001 (Everolimus) in Anaplastic Thyroid Cancer
    Papewalis, C.
    Wuttke, M.
    Schinner, S.
    Willenberg, H. S.
    Baran, A. M.
    Scherbaum, W. A.
    Schott, M.
    HORMONE AND METABOLIC RESEARCH, 2009, 41 (10) : 752 - 756
  • [9] Combination efficacy of mTOR and MEK inhibitor in malignant pleural mesothelioma (MPM).
    Matsumoto, Seiji
    Orui, Hayato
    Kuroda, Ayumi
    Hashimoto, Masaki
    Yoneda, Kazue
    Takuwa, Teruhisa
    Kondo, Nobuyuki
    Hasegawa, Seiki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas
    Kim, S. J.
    Shin, D. -Y.
    Kim, J. S.
    Yoon, D. H.
    Lee, W. S.
    Lee, H.
    Do, Y. R.
    Kang, H. J.
    Eom, H. S.
    Ko, Y. H.
    Lee, S. H.
    Yoo, H. Y.
    Hong, M.
    Suh, C.
    Kim, W. S.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 712 - 718
12345